The CANTOS trial in 2017 demonstrated a proof-of-concept that targeting an inflammatory pathway; i.e. IL-1β with a monoclonal antibody, canakinumab, can modify disease outcomes in people with known CAD and hs-CRP of at least 2 mg/L,159 although the effect size was modest. The gene discussed is IL1B; the disease is coronary artery disorder.